OBJECTIVE: To determine whether survival motor neuron (SMN) expression was stable over time. METHODS: We developed a multiplex real-time reverse transcriptase (RT)-PCR assay to quantify SMN transcripts in preclinical blood samples from 42 patients with spinal muscular atrophy (SMA) drawn for three time points per patient; most blood samples were shipped to a centralized laboratory. RESULTS: We obtained a sufficient amount (9.7 +/- 5.6 microg) of good-quality total RNA, and RNAs were stable for up to a 3-year interval. This allowed RNA samples collected during a 9- to 12-month period to be analyzed in a single run, thus minimizing interexperimental variability. SMN expression was stable over time; intersample variability for baseline measures, collected during a 17-month interval, was less than 15% for 38 of 42 SMA patients analyzed. This variability was well below the 1.95-fold increase in full-length SMN (flSMN) transcripts detected in SMA fibroblasts treated with 10 mM valproic acid. CONCLUSION: Real-time quantification of SMN messenger RNA expression may be a biomarker that is amenable to multicenter SMA clinical trials.
OBJECTIVE: To determine whether survival motor neuron (SMN) expression was stable over time. METHODS: We developed a multiplex real-time reverse transcriptase (RT)-PCR assay to quantify SMN transcripts in preclinical blood samples from 42 patients with spinal muscular atrophy (SMA) drawn for three time points per patient; most blood samples were shipped to a centralized laboratory. RESULTS: We obtained a sufficient amount (9.7 +/- 5.6 microg) of good-quality total RNA, and RNAs were stable for up to a 3-year interval. This allowed RNA samples collected during a 9- to 12-month period to be analyzed in a single run, thus minimizing interexperimental variability. SMN expression was stable over time; intersample variability for baseline measures, collected during a 17-month interval, was less than 15% for 38 of 42 SMA patients analyzed. This variability was well below the 1.95-fold increase in full-length SMN (flSMN) transcripts detected in SMA fibroblasts treated with 10 mM valproic acid. CONCLUSION: Real-time quantification of SMN messenger RNA expression may be a biomarker that is amenable to multicenter SMA clinical trials.
Authors: U R Monani; M Sendtner; D D Coovert; D W Parsons; C Andreassi; T T Le; S Jablonka; B Schrank; W Rossoll; W Rossol; T W Prior; G E Morris; A H Burghes Journal: Hum Mol Genet Date: 2000-02-12 Impact factor: 6.150
Authors: T Frugier; F D Tiziano; C Cifuentes-Diaz; P Miniou; N Roblot; A Dierich; M Le Meur; J Melki Journal: Hum Mol Genet Date: 2000-03-22 Impact factor: 6.150
Authors: Markus Feldkötter; Verena Schwarzer; Radu Wirth; Thomas F Wienker; Brunhilde Wirth Journal: Am J Hum Genet Date: 2001-12-21 Impact factor: 11.025
Authors: Keith B Glaser; Michael J Staver; Jeffrey F Waring; Joshua Stender; Roger G Ulrich; Steven K Davidsen Journal: Mol Cancer Ther Date: 2003-02 Impact factor: 6.261
Authors: Charlotte J Sumner; Thanh N Huynh; Jennifer A Markowitz; J Stephen Perhac; Brenna Hill; Daniel D Coovert; Kristie Schussler; Xiaocun Chen; Jill Jarecki; Arthur H M Burghes; J Paul Taylor; Kenneth H Fischbeck Journal: Ann Neurol Date: 2003-11 Impact factor: 10.422
Authors: L Brichta; Y Hofmann; E Hahnen; F A Siebzehnrubl; H Raschke; I Blumcke; I Y Eyupoglu; B Wirth Journal: Hum Mol Genet Date: 2003-07-29 Impact factor: 6.150
Authors: C J Sumner; S J Kolb; G G Harmison; N O Jeffries; K Schadt; R S Finkel; G Dreyfuss; K H Fischbeck Journal: Neurology Date: 2006-02-15 Impact factor: 9.910
Authors: Honglai L Zhang; Feng Pan; Daewha Hong; Shailesh M Shenoy; Robert H Singer; Gary J Bassell Journal: J Neurosci Date: 2003-07-23 Impact factor: 6.167
Authors: Jonathan J Cherry; Dione T Kobayashi; Maureen M Lynes; Nikolai N Naryshkin; Francesco Danilo Tiziano; Phillip G Zaworski; Lee L Rubin; Jill Jarecki Journal: Assay Drug Dev Technol Date: 2014-08 Impact factor: 1.738
Authors: Matthew E R Butchbach; Casey J Lumpkin; Ashlee W Harris; Luciano Saieva; Jonathan D Edwards; Eileen Workman; Louise R Simard; Livio Pellizzoni; Arthur H M Burghes Journal: Exp Neurol Date: 2016-02-15 Impact factor: 5.330
Authors: Kathryn J Swoboda; Charles B Scott; Thomas O Crawford; Louise R Simard; Sandra P Reyna; Kristin J Krosschell; Gyula Acsadi; Bakri Elsheik; Mary K Schroth; Guy D'Anjou; Bernard LaSalle; Thomas W Prior; Susan L Sorenson; Jo Anne Maczulski; Mark B Bromberg; Gary M Chan; John T Kissel Journal: PLoS One Date: 2010-08-19 Impact factor: 3.240
Authors: Matthew E R Butchbach; Jasbir Singh; Margrét Thorsteinsdóttir; Luciano Saieva; Elzbieta Slominski; John Thurmond; Thorkell Andrésson; Jun Zhang; Jonathan D Edwards; Louise R Simard; Livio Pellizzoni; Jill Jarecki; Arthur H M Burghes; Mark E Gurney Journal: Hum Mol Genet Date: 2009-11-06 Impact factor: 6.150
Authors: Galina Yu Zheleznyakova; Anton V Kiselev; Viktor G Vakharlovsky; Mathias Rask-Andersen; Rohit Chavan; Anna A Egorova; Helgi B Schiöth; Vladislav S Baranov Journal: BMC Med Genet Date: 2011-07-15 Impact factor: 2.103